FDA Inspection
GlaxoSmithKline, LLC.GlaxoSmithKline, LLC. – FDA Inspection, Jan 26, 2018
Record Details
This FDA Inspection record concerns GlaxoSmithKline, LLC., with an inspection on January 26, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 0b5167aa-cc71-4870-ab00-b2a540d138b4
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1043309
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
Other FDA inspections of GlaxoSmithKline, LLC.
6| Date | Classification | Office | Project area |
|---|---|---|---|
| July 15, 2026 | Not classified | Philadelphia District Office | |
| March 7, 2025 | Not classified | Philadelphia District Office | |
| September 25, 2024 | Not classified | Philadelphia District Office | |
| June 20, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 8, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for GlaxoSmithKline, LLC.
- FDA Inspection 1332910 - 2026-07-15
- FDA Inspection 1274978 - 2025-03-07
- FDA Inspection 1261906 - 2024-09-25
- FDA Inspection 1211050 - 2023-06-20
- FDA Inspection 927643 - 2015-05-08
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.